In contrast to the observation in AML PDX models, 20F2 showed negligible inhibitory effects on the engraftment of normal cells, including total hCD45+ cells, hCD19+ lymphoid cells, and CD33+ myeloid cells (Fig. 7k, Supplementary Fig. 7l), which could be a consequence of relatively low surface TMIGD2 expression and intrinsic relative TMIGD2-signaling independence in HSPCs. The gene discussed is CD33; the disease is acute myeloid leukemia.